Gentronix will be showcasing its latest product and service developments at the Society of Toxicology 49th Annual Meeting and ToxExpo at booth 1919 to be held in Salt Lake City. New
research using 75 marketed pharmaceuticals shows Green-Screen HC from Gentronix is more predictive for genotoxic carcinogenicity than existing regulatory in vitro assays. Published
in Mutagenesis, the analysis provides additional evidence to support the use of the Gentronix assay in the early identification of genotoxic liability or in non-clinical safety assessment
of candidate pharmaceuticals during development. As well as more accurate prediction of in vivo genotoxicity (88%) and genotoxic carcinogenicity (93%) than other in vitro genotoxicity tests, the assay
maintained its high specificity: no new genotoxicity and/or carcinogenicity alerts were produced for any of the compounds tested.
Polls
Loading ...